Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 7/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | AHR | P35869 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4028968 | 1.00 | ESR2 (0.38) | ESR2MAPTL3MBTL1SMN1; SMN2ALDH1A1 | |
| SCHEMBL4032009 | 0.72 | ESR2 (0.39) | ESR2MAPTL3MBTL1SMN1; SMN2ALDH1A1 | |
| SCHEMBL25983222 | 0.72 | ESR2 (0.49) | ESR2MAPTL3MBTL1SMN1; SMN2ALDH1A1 | |
| SCHEMBL6623690 | 0.71 | MAPT (0.39) | ESR2MAPTL3MBTL1SMN1; SMN2ALDH1A1 | |
| SCHEMBL3070066 | 0.70 | ESR2 (0.45) | ESR2MAPTL3MBTL1SMN1; SMN2ALDH1A1 | |
| SCHEMBL1847303 | 0.69 | ESR2 (0.58) | ESR2MAPTL3MBTL1SMN1; SMN2ALDH1A1 | |
| SCHEMBL4250271 | 0.65 | KDM4E (0.48) | ESR2MAPTL3MBTL1ALDH1A1NPC1 | |
| SCHEMBL4251655 | 0.65 | KDM4E (0.48) | ESR2MAPTL3MBTL1ALDH1A1NPC1 | |
| SCHEMBL4250277 | 0.65 | KDM4E (0.48) | ESR2MAPTL3MBTL1ALDH1A1NPC1 | |
| SCHEMBL7707955 | 0.64 | NPC1 (0.46) | ESR2MAPTL3MBTL1SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1470113-B1 | PYRIMIDINONE VIRAL POLYMERASE INHIBITORS | ANGELETTI P IST RICHERCHE BIO (IT) | 2009-01-07 | — | — | EP | disclosed |
| US-20050130997-A1 | Pyrimidinone viral polymerase inhibitors | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2005-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130997-A1 | Pyrimidinone viral polymerase inhibitors | POLR2A, POLR1E, POLR2E | ESR2 3067/4885MAPT 3658/4885L3MBTL1 3083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.